NCT02392026View on ClinicalTrials.gov

Safety and Tolerability of Metronidazole Gel 1.3%

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 12, 2015

Primary Completion Date

October 5, 2016

Study Completion Date

October 5, 2016

Conditions
Vaginosis, Bacterial
Interventions
DRUG

Metronidazole Gel

Metronidazole Vaginal Gel 1.3% administered via applicator

Trial Locations (8)

38104

Allergan Research Site #321, Memphis

40004

Allergan Research Site #315, Bardstown

43231

Allergan Research Site #319, Columbus

45406

Allergan Research Site #322, Dayton

70115

Allergan Research Site #314, New Orleans

75062

Allergan Research Site #316, Irving

90723

Allergan Research Site #324, Paramount

90806

Allergan Research Site #318, Long Beach

Sponsors

Lead Sponsor

Insud Pharma
All Listed Sponsors
collaborator

Allergan Sales, LLC

INDUSTRY

lead

Insud Pharma

INDUSTRY

NCT02392026 - Safety and Tolerability of Metronidazole Gel 1.3% | Biotech Hunter | Biotech Hunter